Cinobufacini injection for moderate and advanced primary liver cancer: A systematic review and meta-analysis

doi:10.5246/jcps.2019.04.027

Abstract

Abstract:

Cinobufacini, a compound extracted from bufo toad, is a traditional Chinese medicine (TCM) that has been shown to have efficacy in cancer treatment. The cinobufacini injection is widely used in patients with moderate and advanced liver cancer in China. In the present study, we aimed to determine the effects of cinobufacini injection for this specific category of patients.A search for randomized control trials (RCTs) using cinobufacini was conducted in the PubMed, EMBASE, CENTRAL, and the other four major Chinese databases. The systematic review was performed according to the recommendations of the Cochrane collaboration, and the RevMan 5.3. software was used for statistical analysis. A random-effects model was used to perform the data. Risk ratios (RR) with corresponding 95% confidence interval were calculated according to Cochrane handbook.A total of 11 RCTs consisting of 728 patients were included. All of the trials demonstrated significantly improved total response rates, total response rates of Karnofsky Performance Score (KPS), 1- to 2-year survival rates, and quality of life in the intervention groups injected with cinobufacini. There was no statistically significant difference between the groups (cinobufacini versus no cinobufacini; cinobufacini plus transcatheter arterial chemoembolization (TACE) versus TACE only) in terms of the 6-month survival rate, clinical benefit rate and clinical benefit rate of KPS. This systematic review demonstrated the beneficial effects of cinobufacini injection in terms of total response rate and the 1- to 2-year survival rate in patients with moderate and advanced liver cancer. The efficacy for the cinobufacini injection group might be better than that of the control group for treatment of moderate and advanced liver cancer. Given that the majority of the trials were of low quality, more high-quality prospective RCTs with strict design in accordance with CONSORT for TCM are needed.

Key words: Cinobufacini injection, Liver cancer, Meta-analysis, Chinese herb medicine, Alternative therapies

CLC Number:

R954

Supporting:

Zhiyong Dong, Xiantu Qiu, Stacy A. Kujawa, S.M. Shariful Islam, Jie Zhang. Cinobufacini injection for moderate and advanced primary liver cancer: A systematic review and meta-analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(4): 264-275.

References

[1] Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA. Cancer J. Clin. 2019, 69, 7-34.

[2] Kao, J.H.; Chen, D.S. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int. 2005, 25, 696-703.

[3] Chen, W.Q.; Zheng, R.S.; Baade, P.D.; Zhang, S.W.; Zeng, H.M.; Bray, F.; Jemal, A.; Yu, X.Q.; He, J. Cancer statistics in China, 2015. CA. Cancer J. Clin. 2016, 66, 115-132.

[4] Ling, C.Q.; Yue, X.Q.; Ling, C. Three advantages of using traditional Chinese medicine to prevent and treat tumor. J. Integr. Med. 2014, 12, 331-335.

[5] Wang, X.B.; Wang, N.; Cheung, F.; Lao, L.X.; Li, C.; Feng, Y.B. Chinese medicines for prevention and treatment of human hepatocellular carcinoma: Current progress on pharmacological actions and mechanisms. J. Integr. Med. 2015, 13, 142-164.

[6] Qi, F.H.; Zhao, L.; Zhou, A.Y.; Zhang, B.; Li, A.Y.; Wang, Z.X.; Han, J.Q. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 2015, 9, 16-34.

[7] Chen, Z.; Chen, H.Y.; Lang, Q.B.; Li, B.; Zhai, X.F.; Guo, Y.Y.; Yue, X.Q.; Ling, C.Q. Preventive effects of jiedu granules combined with cinobufacini injection versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: a case-control trial. Chin. J. Integr. Med. 2012, 18, 339-344.

[8] Qi, F.H.; Li, A.Y.; Zhao, L.; Xu, H.L.; Inagaki, Y.; Wang, D.L.; Cui, X.Y.; Gao, B.; Kokudo, N.; Nakata, M.; Tang, W. Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells. J. Ethnopharmacol. 2010, 128, 654-661.

[9] Zhu, X.Y.; Liu, L.M. Research progress on the antitumor mechanism of cinobufacini injection and its active ingredient. Tumor. J. World. 2006, 5, 272-275.

[10] Yang, L.H.; Zhang, H.Z.; Zhang, B.; Chen, F.; Lai, Z.H.; Xu, L.F.; Jin, X.Q. Studies on the chemical constituents from the skin of Bufo bufo gargarizans cantor. J. Shenyang Pharm. Univ. 2000, 17, 292-295.

[11] Qi, F.H.; Li, A.Y.; Inagaki, Y.; Kokudo, N.; Tamura, S.; Nakata, M.; Tang, W. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int. Immunopharmacol. 2011, 11, 342-349.

[12] He, W. Effects of TCM cinobufotalin on immune function in patients with advanced malignancies. Clin. J. Chin. Med. 2014, 6, 19-20.

[13] Cui, X.Y.; Inagaki, Y.; Xu, H.L.; Wang, D.L.; Qi, F.H.; Kokudo, N.; Fang, D.Z.; Tang, W. Anti-hepatitis B virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2.2.15 cells. Biol. Pharm. Bull. 2010, 33, 1728-1732.

[14] Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009, 45, 228-247.

[15] Karnofsky, D.A.; Burchenal, J.H. The clinical evaluation of chemotherapeutic agents in cancer. (ed. MacLeod, C.M.) Evaluation of chemotherapeutic agents. New York: Columbia University Press 1949,196.

[16] Higgins, J.P.T.; Green, S. (eds). Cochrane handbook for systematic reviews of interventions, version 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011. http://www.cochranehandbook.Org.

[17] Review Manager (RevMan) [Computer program]. Version [5.3]. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. 2014.

[18] Brusselaers, N. How to teach the fundamentals of meta-analyses. Ann. Epidemiol. 2015, 25, 948-954.

[19] Higgins, J.P.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21, 1539-1558.

[20] Takkouche, B.; Khudyakov, P.; Costa-Bouzas, J.; Spiegelman, D. Confidence intervals for heterogeneity measures in meta-analysis. Am. J. Epidemiol. 2013, 178, 993-1004.

[21] Wu, T.; Sun, R.M.; Wang, Z.X.; Yang, W.Y.; Shen, S.H.; Zhao, Z.J. A meta-analysis of Cinobufacini combined with transcatheterarterial chemoembolization in the treatment of advanced hepatocellular carcinoma. J. Cancer. Res. Ther. 2014, 10, 60-64.

[22] Chen, Z.; Zhai, X.F.; Su, Y.H.; Wan, X.Y.; Li, J.; Xie, J.M.; Gao, B. Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer. J. Chin. Integ. Med. 2003, 1, 184-186.

[23] Deng, Z.Y.; Duan, H.B.; Deng, Z.Y.; Duan, H.B. Clinical observation of Cinobufacini injection combined with TACE in the treatment of hepatocellular carcinoma. Tianjin J. tradit. Chin. Med. 2015, 32, 275-278.

[24] Shen, J.J.; Tan, S.Z.; Shen, J.J.; Tan, S.Z. Transcatheter arterial embolization with cinobufacini on terminal stage of hepatocellular carcinoma. Jilin J. tradit. Chin. Med. 2015, 678-680.

[25] Wang, Y.F. TACE combined cinobufotalin treatment for primary liver cancer. J. Basic Clin. Oncol. 2014, 27, 417-418.

[26] Zhao, Z.G.; Tang, Z.Q. The clinical value of cinobufacini injection care for liver cancer. Inn. Mong. Med. J. 2014, 47, 172-175.

[27] Mao, W.D. The recurrence of cinobufacini injection intervention after resection of hepatocellular carcinoma. Anhui Med. Pharm. J. 2013, 17, 2144-21445.

[28] Huang, Z.F.; Li, H.Z.; Chen, Q.S. Effects on the life quality and immune function of cinobufacini injection in the treatment of advanced primary liver cancer. J. Yunan Univ. tradit. Chin. Med. 2009, 32, 47-48.

[29] Ni, B.Q.; Zhang, Z.H.; Chen, R.X. Role of Cinobufacini injection combines with supportive care for advanced hepatoma. Int. Med. China. 2009, 4, 197-199.

[30] Li, Q.; Sun, B.M.; Peng, Y.H. Clinical study on the treatment of primary liver cancer by Cinobufatain combined with transcatheter arterial chemoembolization. J. Shanghai Univ. tradit. Chin. Med. 2008, 22, 32-34.

[31] Zhou, J.S.; Lu, H.; Wu, X.D.; Xu, X.; Zhou, J.S.; Lu, H.; Wu, X.D.; Xu, X. Effects of huachan-shu injection combind with transcatheter arterial chemoembolization on patients with advanced unresectable hepatocelluler carcinoma. Chin. J. Prim. Med. Pharm. 2006, 13, 571-572.

[32] Chen, Z. Clinical observation of cinobufacini injection used to reat moderate and advanced primary liver cancer. Chin. J. Integr. Tradit. West. Med. 2003, 1, 184-186.

[33] Yang, X.Y.; Jia, C.H. Understanding association of spleen system with earth on traditional Chinese medicine theory. J. Tradit. Chin. Med. 2013, 33, 134-136.

[34] Zhang, C.; Wan, D.M.; Cao, W.J. Reversal effect of cinobufacini on multidrug resistance of Raji/ADR cells and its mechanisms. J. Exp. Hematol. 2014, 22, 1306-1310.

[35] Wu, X.; Gao, B.; Yang, J.; Bian, B.L.; Wang, H.J. In vitro anti-proliferation effect of peptides from cinobufacini injection. Acta Pharm. Sin. 2012, 47, 822-826.

[36] Xia, J.F.; Inagaki, Y.; Gao, J.J.; Qi, F.H.; Song, P.P.; Han, G.H.; Sawakami, T.; Gao, B.; Luo, C.; Kokudo, N.; Hasegawa, K.; Sakamoto, Y.; Tang, W. Combination of cinobufacini and doxorubicin increases apoptosis of hepatocellular carcinoma cells through the fas- and mitochondria-mediated pathways. Am. J. Chin. Med. 2017, 45, 1537-1556.

[37] Xie, R.F.; Li, Z.C.; Chen, P.P.; Zhou, X. Bufothionine induced the mitochondria-mediated apoptosis in H22 liver tumor and acute liver injury. Chin. Med. 2015, 10, 5.

[38] Liu, L.; Chen, B.A.; Qin, S.K. Anti-angiogenesis effect of arsenic trioxide plus cinobufacin on human hepatocarcinoma transplantation model nude mice. Chin. J. Integr. Tradit. West. Med. 2011, 31, 67-72.

[39] Schulz, K.F.; Altman, D.G.; Moher, D.; CONSORT Group, CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomized trials. Open Med. 2010, 4, e60-e68.

[40] Moher, D.; Hopewell, S.; Schulz, K.F.; Montori, V.; Gøtzsche, P.C.; Devereaux, P.J.; Elbourne, D.; Egger, M.; Altman, D.G.; CONSORT, CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. Int. J. Surg. 2012, 10, 28-55.

[41] Bian, Z.X.; Liu, B.Y.; Moher, D.; Wu, T.X.; Li, Y.P.; Shang, H.C.; Cheng, C. Consolidated standards of reporting trials (CONSORT) for traditional Chinese medicine: Current situation and future development. Front. Med. 2011, 5, 171-177.

[42] Simin Yang, Siwang Yu. The 4th Cancer Chemoprevention Symposium, Beijing 2016—Cancer Chemoprevention by Dietary Phytochemicals and Traditional Chinese Medicines. J. Chin. Pharm. Sci. 2016, 25, 704-706.